Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on REVOLYMER PLC. We currently have 27 research reports from 2 professional analysts.
|02Nov16 01:18||RNS||Divestment of Nicotine Gum Business|
|14Oct16 07:00||RNS||Director/PDMR Shareholding|
|06Oct16 07:00||RNS||Director/PDMR Shareholding|
|30Sep16 07:00||RNS||Director/PDMR Shareholding|
|22Sep16 07:00||RNS||Interim Results|
|19Sep16 07:00||RNS||Divestment of Nicotine Gum Business|
|13Sep16 11:34||RNS||Directorate Change|
Frequency of research reports
Research reports on
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Panmure Morning Note 22-09-2016
22 Sep 16
Interims this morning focus, naturally, on the events that will underpin the shape of the business both now and over the longer-term: the acquisition of Itaconix and the divestment of the nicotine gum business to Alkalon A/S (see our notes of 19 August and 19 September respectively).
Panmure Morning Note 07-09-2016
07 Sep 16
The first commercial sale of Itaconix CHT for use in a private label automatic dish wash (ADW) detergent represents an important milestone for Revolymer following the acquisition of the business during the summer. Having already established use for its itaconic acid polymers in leading, private label European and North American detergent brands for water conditioning, new regulations scheduled to take effect in 2017 which will limit phosphate use in European ADW detergents. We see considerable opportunities against such a backdrop and consider the combined technology platforms of Revolymer/Itaconix offer further future opportunities in terms of product pipeline potential. Repeat Buy.
Itaconix: strategic reshaping
18 Aug 16
An acquisition, a placing and the proposed transfer of the nicotine gum assets to a (currently undisclosed) European player add up to material reshaping of the business and one which we believe will position the enlarged group very well for the future. Itaconix’s focus fits well with Revolymer’s existing target markets – initially in Home Care and with significant future opportunities in Personal Care – and we believe the expanded product offering and pipeline will drive future growth based on a broader specialty polymer platform. We reinstate a Buy recommendation and target price of 70p (81p).
Result of General meeting
11 Jul 16
Further to our note of 21 June 2016, Revolymer announced on 8 July that all resolutions were passed at the General Meeting held in connection with the proposed Placing and the Woodford Additional Investment. The 10,810,811 placing shares and 4,869,411 additional Woodford placing shares are expected to be admitted to trading today, 11 July 2016. We placed our recommendation to Under Review for regulatory purposes on 21 June 2016 and will update in due course
Innovate, specialise, integrate, globalise
01 Dec 16
Carclo has refocused investment in its established businesses (Technical Plastics and LED Technologies), where a differentiated offer and long-term relationships with customers provide good earnings visibility and more certainty of a return. This strategy delivered strong revenue and profits growth during H117. This growth appears set to continue, underpinned by long-term relationships with blue-chip customers. We leave our estimates and indicative valuation broadly unchanged and introduce our estimates for FY19.
N+1 Singer - Morning Song 06-12-2016
06 Dec 16
With FY16 volume and revenue already disclosed in the pre-close, the focus in today’s prelims is on PBT (£100.3m versus our £101m) and EPS (96.8p versus our 95.4p). No special dividend triggered this year (none forecast) and DPS is held at 46.8p (N1SE: 48.0p). On end markets, recent commentary is reiterated – the core business is growing, whilst consumer electronics will be subdued in the current year (competitive capacity from Solvay). On currency, there will be a material benefit in the current year (a little more than the £14m to £15m previously indicated), and a further tailwind next year if current rates are maintained (quantum TBC). There is also an investment of £10m today in a minority interest in Magma Global, Victrex’ oil and gas mega programme partner. Although the share price is now close to our TP of 1730p, we feel that there is enough in today’s announcement to retain a positive stance on medium term opportunities with strong cashflow and a special dividend potentially to look forward to in the current year.
30 Nov 16
Results have yet again beaten our forecasts and the management has now delivered the fourth consecutive year of earnings above expectations. The share price is up 41% over the last three months, and Treatt is steadily moving from commoditised sales to more value-added products. Its strategy of deep customer relationships is paying off, giving it a real competitive advantage and improving margins. The year finished strongly and momentum is due to continue in the traditionally seasonally weaker Q117. Our P&L forecasts are broadly maintained, but our fair value moves to 272p (from 240p) as a result of stronger cash flow.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.